Navigation Links
US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium

THE WOODLANDS, Texas, Dec. 14 /PRNewswire/ -- Seven leading cancer physicians and investigators affiliated with US Oncology Research participated in studies that were presented orally at the 2009 San Antonio Breast Cancer Symposium, held Dec. 9-13 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. Fifteen others presented their research in poster presentations during the conference.

Stephen Jones, M.D., medical director for US Oncology Research, co-chair of the US Oncology Breast Cancer Research Committee, and physician at Texas Oncology-Dallas, and Lina Asmar, Ph.D., director of Biostatistics and Medical Writing at US Oncology, were co-authors on a team that presented results at 9:15 a.m. on Thursday, Dec. 10, regarding the five-year analysis of the TEAM (Tamoxifen Exemestane Adjuvant Multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. The study was titled "Five years of exemestane as initial therapy compared to 5 years of tamoxifen followed by exemestane: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone-sensitive early breast cancer."

"The TEAM trial is the largest aromatase inhibitor study ever to be conducted. The overall results are positive with an improvement in outcome measured by several parameters and a favorable safety profile for exemestane relative to a worldwide standard, tamoxifen," said Dr. Jones. "This very large study is a treasure trove of substudies, providing valuable scientific information for women with breast cancer."

Dr. Jones was also an investigator in Thursday's 9:30 a.m. oral presentation, titled, "Disease related outcome with long term follow-up: an updated analysis of the Intergroup Exemestane Study (IES)" and several poster sessions listed below. Dr. Asmar also co-authored many of the poster presentations listed below.

Nicholas Robert, M.D., investigator at Fairfax-Northern Virginia Hematology-Oncology, an affiliate of US Oncology, participated in three oral presentations at the symposium:

  • The 9:45 a.m. oral presentation on Thursday, Dec. 10, titled, "Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC CTG MA17 Trial."
  • The 9:45 a.m. presentation on Saturday, Dec. 12, titled, "Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC[rarr]T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC[rarr]TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study."
  • The 10:15 a.m. presentation on Saturday, Dec. 12, titled, "Analysis of Fcy receptor IIA & IIIA polymorphisms: correlation with outcome in trastuzumab-treated HER2/Neu amplified early and metastatic breast cancer patients."

Dr. Robert also co-authored many poster sessions listed below.

Ragene Rivera, M.D., investigator at Texas Oncology-El Paso West, an affiliate of US Oncology, participated in the RIBBON-2 study: "A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of Bevacizumab in combination with chemotherapy for second-line treatment of HER@-negative metastatic breast cancer" presented orally at 3 p.m. Friday, Dec. 11.

Joyce O'Shaughnessy, M.D., investigator with Texas Oncology-Baylor at Sammons Cancer Center, an affiliate of US Oncology, was an investigator on the team that presented the 9:30 a.m. general session on Saturday, Dec. 12 titled, "Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy." Dr. O'Shaughnessy also co-authored several poster sessions listed below.

In addition to the above oral presentations, US Oncology affiliated physicians presented the following poster sessions:

Poster session 1, Thursday, Dec. 10:

Poster session 2, Friday, Dec. 11:

  • Dr. O'Shaughnessy; Suzanne Muller, Jessica Donato-Jensen, and Lina Asmar, Ph.D., all with US Oncology Research co-authored #2014, "Potential predictive markers of benefit from cetuximab in metastatic breast cancer: an analysis of two randomized phase 2 trials."
  • Ruth Oratz, M.D. of New York University School of Medicine was co-author of #2031 "Effect of 21-gene recurrence score results on treatment recommendations in patients with lymph node-positive, estrogen receptor-positive breast cancer."
  • David Loesch, M.D., previously of Central Indiana Cancer Centers, an affiliate of US Oncology; Kristi McIntyre. M.D. of Texas Oncology-Dallas Presbyterian Hospital, an affiliate of US Oncology; Lina Asmar, Ph.D., Feng Zhan and Kristi Boehm all with US Oncology Research; and Dr. O'Shaughnessy co-authored #2105 "Three-year follow-up of survival and progression in a phase II trial of Gemcitabine plus Carboplatin (plus Trastuzumab in HER2+ patients) in metastatic breast cancer patients."
  • Cristi Aitelli, D.O. of Texas Oncology-SW Fort Worth, an affiliate of US Oncology; Lina Asmar, Ph.D.; Dr. Jones; and John Pippen, M.D., F.A.C.P., of Texas Oncology-Baylor at Sammons Cancer Center, an affiliate of US Oncology, co-authored #2134, "Analysis of topoisomerase Ila and HER2 status in 126 patients from the US Oncology 9735 trial of adjuvant chemotherapy with docetaxel/cyclophosphamide (TC) vs doxorubicin/cyclophosphamide (AC) in early breast cancer."
  • Dr. O'Shaughnessy co-authored #207, "Comparison of subgroup analysis of PFS from three phase III studies of Bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer (MBC)."
  • Dr. Robert co-authored #208, "Analysis of bevacizumab (Bev) therapy, bisphosphonate use and osteonecrosis of the jaw (ONJ) in >1900 patients treated in two randomized, controlled trials."

Poster session 3

  • Dr. O'Shaughnessy, Cynthia Osborne, M.D., and Dr. Pippen, all of Texas Oncology-Baylor at Sammons Cancer Center, an affiliate of US Oncology, co-authored #3122, "Final results of a randomized phase II study demonstrating efficacy and safety of BSI-201, a poly (ADP-Ribose) polymerase (PARP) inhibitor, in combination with gemcitabine/carboplatin (G/C) in metastatic triple negative breast cancer (TNBC)."
  • Dr. Oratz co-authored #3085, "Importance of providing tailored resources to patients with metastatic breast cancer: results of the global BRIDGE survey."

Poster session 5

Poster session 6

  • Dr. Robert co-authored #6083, "Phase III studies of bevacizumab (B) in combination with chemotherapy in patients with Her2-negataive metastatic breast cancer (MBC): summary of selected adverse events."
  • Dr. Robert and Dr. O'Shaughnessy co-authored #6084, "Clinical benefit rate of time to response in RIBBON-1, a randomized, double-blind, phase III trial of chemotherapy with or without bevacizumab (B) for the first-line treatment of Her2-negative locally recurrent or metastatic breast cancer (MBC)."
  • Lea Krekow, M.D., of Texas Oncology-The Breast Care Center of North Texas, an affiliate of US Oncology; Dr. Collea; Steven Papish of Atlantic Health Systems; Angel G. Negron. M.D. of Texas Oncology-Fort Worth, an affiliate of US Oncology; Regina Resta, M.D. of New York Oncology Hematology-Amsterdam, an affiliate of US Oncology; Sasha J. Vukelja, M.D., F.A.C.P., of Texas Oncology-Tyler, an affiliate of US Oncology; Jessica Donato-Jensen, Laura Guerra and Lina Asmar, Ph.D., with US Oncology Research; and Dr. O'Shaughnessy co-authored #6097, "Incidence of and Predictive factors for recovery of ovarian function on Letrozole in ER-positive breast cancer patients in their forties who cease menstruating with adjuvant chemotherapy."
  • John W. Smith II, M.D., of Northwest Cancer Specialists-Providence Medical Center, an affiliate of US Oncology; Dr. Vukelja; Amy C. Rabe, M.D. of Kansas City Cancer Centers-Southwest, an affiliate of US Oncology; Robert E. Pluenneke. M.D. of Kansas City Cancer Center-North, an affiliate of US Oncology; Nichole L. Wentworth-Hartung. M.D. of Minnesota Oncology-Woodbury, an affiliate of US Oncology; Linda B. Benaderet, D.O. of Arizona Oncology-Phoenix, an affiliate of US Oncology; Nicholas W. Koutreloakos, M.D. of Maryland Oncology Hematology, P.A.-Columbia, an affiliate of US Oncology; Gerald J. Robbins, M.D. of Florida Cancer Institute-New Port Richey, an affiliate of US Oncology; Spencer H. Shao, M.D. of Northwest Cancer Specialists-Rose Quarter, an affiliate of US Oncology; Yunfei Wang, Kristi Boehm, and Lina Asmar, Ph.D., with US Oncology Research; and Dr. O'Shaughnessy co-authored #6099, "Preliminary toxicity results of a phase II randomized trial of weekly or every 3-week ixabepilone in metastatic breast cancer (MBC)."
  • Dr. Jones co-authored #605, "Consistency of Effect of Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer independent of nodal status: meta-analysis of 12 randomized clinical trials."

About US Oncology Research

With experienced investigators and dedicated research nurses, US Oncology Research represents the largest research network specializing in Phase I-IV oncology clinical trials in the United States. US Oncology Research serves more than 80 sites in 200 locations with over 70 open trials being managed at any given time.

Supported by US Oncology, Inc., the network has played a role in the development of 39 cancer therapies approved by the Food and Drug Administration; more than 38,500 patients have participated in clinical trials. For more information, visit the company's Web site,

About US Oncology

US Oncology, Inc., headquartered in The Woodlands, Texas, works closely with physicians, payers, biotechnology, pharmaceutical and medical equipment manufacturers, to identify and deliver innovative services that enhance patient access to advanced cancer care. US Oncology supports one of the nation's foremost cancer treatment and research networks, accelerating the availability and use of evidence-based medicine and shared best practices.

US Oncology uses its expertise to support every aspect of the cancer care delivery system--from drug development to distribution and outcomes measurement--enabling the company to help increase the efficiency and safety of cancer care. According to the company's last quarterly earnings report, US Oncology is affiliated with 1,310 physicians operating in 493 locations, including 98 radiation oncology facilities in 39 states. For more information, visit the company's Web site,

SOURCE US Oncology

SOURCE US Oncology
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
3. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
4. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
5. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
6. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
7. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
8. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
9. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
10. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
11. Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
Post Your Comments:
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
Breaking Medicine News(10 mins):